Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Abstract Despite the emergence of new strategies in recent years, multiple myeloma (MM) is still an incurable disease with poor outcome. As a new treatment, chimeric antigen receptor (CAR‐) T cell therapy brought exciting news to patients with relapsed or refractory MM. B‐cell maturation antigen (BC...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-12-01
|
Series: | ImmunoMedicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/imed.1030 |